A Federal Adaptive, On-Demand Pharmaceutical Manufacturing Initiative
The COVID-19 pandemic has highlighted the urgent need to address lags in American pharmaceutical manufacturing. An investment of $5 billion over five years will improve U.S. pharmaceutical manufacturing infrastructure, including the development of new technologies that will enable the responsive, end-to-end, on-demand production of up to half of the Food and Drug Administration (FDA) list of 223 essential medicines by year two, and the entire portfolio by year five. Spearheading improvements in domestic manufacturing capacity, coupled with driving the advancement of new adaptive, on-demand, and other advanced medicine production technologies will ensure a safe, responsive, reliable, and affordable supply of quality medicines, improving access for all citizens, including vulnerable populations living in underserved urban communities, rural areas, and tribal territories.
Inconsistent data collection makes disaster resilience more challenging than it needs to be. By opening up and making this data consistent, the Biden-Harris Administration can change the way we prepare and mitigate disaster for the better.
The Wildland Fire Mitigation and Management Commission called for input from diverse stakeholders and FAS, along with partners Conservation X Labs (CXL), COMPASS, and the California Council on Science and Technology (CCST), answered the call. Recruiting participants from academia, the private sector, national labs, and other nonprofits, the Wildland Fire Policy Accelerator produced 24 ideas […]
The U.S. is facing a shortage in both pilot-scale and manufacturing-scale biomanufacturing facilities that severely hinders product development and commercialization.
The space economy is enormous, but one of its biggest challenges is tiny: space debris.